$300M Boost for BRAIN

Mix of public, private, philanthropic, and academic investments will fund additional BRAIN Initiative-related projects.

Written byTracy Vence
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

ISTOCK, CHINZOGZAGPresident Obama’s BRAIN Initiative will receive an additional $300 million in funding thanks to an influx of public, private, philanthropic, and academic investments, the White House announced today (September 30). In addition, the US Food and Drug Administration (FDA) and the Intelligence Advanced Research Projects Agency (IARPA) join the National Institutes of Health (NIH), the National Science Foundation (NSF), and the Defense Advanced Research Projects Agency (DARPA) in supporting the initiative. Further, the NIH today announced $46 million in grants for BRAIN, which was launched in April 2013 and aims to fully map the human brain.

Given the variety of funding partners, “I see something emerging that’s very different from other science initiatives that we’ve seen previously,” said said Paul Alivisatos of the University of California, Berkeley, who moderated a panel at today’s White House BRAIN Conference. “BRAIN may turn out to be a model of what a new science initiative is.”

“There’s a big gap between what we want to do in brain research and the technologies available to make exploration possible,” NIH Director Francis Collins said in the statement. “These initial awards are . . . focused on developing the tools and technologies needed to make the next leap in understanding the brain.”

“The BRAIN Initiative is truly an exciting and potentially game-changing effort to unlock the secrets of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies